Study search
Go straight to the source
Search PubMed, Europe PMC and ClinicalTrials.gov from one box. Results come from the indexes themselves, newest first, each linked to its original record.
Amiravo's reviewed summary: Eloralintide research reference →
10 records · open this search in PubMed
- PubMedReviewBeyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.Pharmacological research · 2026 Oct
- PubMedReviewNew Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026 Sep 28
- PubMedCardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism: Emerging Cardiovascular Implications of Eloralintide.Cardiology in review · 2026 Sep 16
- PubMedReviewAmylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.Diabetes, obesity & metabolism · 2026 Sep
- PubMedReviewObesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.Metabolism open · 2026 Jun
- PubMedNetwork Meta-AnalysisReviewNovel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.Endocrinology, diabetes & metabolism · 2026 May
- PubMedRandomized Controlled TrialClinical Trial, Phase IMulticenter StudyEloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.Diabetes, obesity & metabolism · 2026 Apr
- PubMedReviewLong-acting amylin-related peptides as therapies for obesity and type 2 diabetes.Peptides · 2026 Mar
- PubMedRandomized Controlled TrialClinical Trial, Phase IIMulticenter StudyEloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.Lancet (London, England) · 2025 Dec 6
- PubMedClinical Trial, Phase IRandomized Controlled TrialResearch Support, Non-U.S. Gov'tEloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.Molecular metabolism · 2025 Dec
Queries go directly from your browser to NCBI, EMBL-EBI and ClinicalTrials.gov; Amiravo does not store them. Study-type labels come from the indexes and can be wrong. A record's presence says nothing about whether a compound works or is safe. PubMed data via NCBI E-utilities; see NCBI policies.